medigraphic.com
Órgano Oficial de la Asociación Mexicana de Hepatología

2017, Número 1

<< Anterior Siguiente >>

Ann Hepatol 2017; 16 (1)


Association Between Hepatitis B Virus and Chronic Kidney Disease: a Systematic Review and Meta-analysis

Fabrizi F, Donato FM, Messa P

Idioma: Ingles.
Referencias bibliográficas: 43
Paginas: 21-47
Archivo PDF: 295.53 Kb.


RESUMEN

Sin resumen.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Eggers P. Has the incidence of end-stage renal disease in the USA and other countries stabilized? Curr Opin Nephrol Hypertens 2011; 20: 241-5.

  2. Chacko E, Surrun S, Mubarack Sani T, Pappachan J. Chronic viral hepatitis and chronic kidney disease. Postgrad Med J 2010; 86: 486-92.

  3. Fabrizi F, Verdesca S, Messa P, Martin P. Hepatitis C virus infection increases the risk of developing chronic kidney disease: a systematic review and meta-analysis. Dig Dis Sci 2015; 60: 3801-13.

  4. Fabrizi F, Dixit V, Martin P, Messa P. Hepatitis C virus increases the risk of kidney disease among HIV-positive patients: systematic review and meta-analysis. J Med Virol 2016; 88: 487-97.

  5. Johnson R, Couser W. Hepatitis B infection and renal disease: clinical, immunopathogenetic and therapeutic considerations. Kidney Int 1990; 37: 663-76.

  6. Zeng C, Chen H, Wang R, Chen Y, Zhang S, Liu L, Li L, et al. Aetiology and clinical characteristics of membranous nephropathy in Chinese patients. Am J Kidney Dis 2008; 52: 691-8.

  7. Deng C, Song W, Liang H, Feng C, Sheng Y, Wang M. Chronic hepatitis B serum promotes apoptotic damage in human renal tubular cells. World J Gastroenterol 2006; 12: 1752-6.

  8. Pais R, Rusu E, Zilisteanu D, Circiumaru A, Micu L, Voiculescu M, Poynard T, et al. Prevalence of steatosis and insulin resistance in patients with chronic hepatitis B compared with chronic hepatitis C and non-alcoholic fatty liver disease. Eur J Intern Med 2015; 26: 30-6.

  9. Pawlak K, Pawlak D, Mysliwiec M. Hepatitis intensified oxidative stress, MIP-1 beta and RANTES plasma levels in uraemic patients. Cytokine 2004; 28: 197-204.

  10. Liberati A, Altman D, Tetzlaff J, Mulrow C, Gotzsche P, Ioannidis J, Clarke M, (PRISMA Group). The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009; 62: e1-e34.

  11. Poynard T, Conn H. The retrieval of randomised clinical trials in liver diseases from the medical literature: a comparison of Medlars and manual methods. Control Clin Trials 1985; 6: 271-9.

  12. Institute OHR. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Disponible en: http://www.ohri.ca/programs/clinical_ epidemiology/oxford.asp (access date 26 Apr 2014).

  13. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(Suppl. 1): S1-S266.

  14. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7: 177-88.

  15. Petitti D. Approaches to heterogeneity in meta-analysis. Stat Med 2001; 20: 3625-33.

  16. Higgins J, Thompson S, Deeks J, Altman D. Measuring inconsistencies in meta-analysis. Br Med J 2003; 327: 557-60.

  17. Lo M, Lee K, Chan N, Leung W, Ko G, Chan W, So W, et al. Effects of gender, Helicobacter pylori and hepatitis B virus serology status on cardiovascular and renal complications in Chinese type 2 diabetics with overt nephropathy. Diabetes Obesity Metabolism 2004; 6: 223-30.

  18. Lee J, Lin M, Chang J, Hung C, Chang J, Chen H, Yu M, et al. Hepatitis C virus infection increases risk of developing endstage renal disease using competing risk analysis. Plos One 2014; 9: e100790.

  19. Cheng A, Kong P, Wong V, So W, Chan H, Ho C, Lam C, et al. Chronic hepatitis B viral infection independently predicts renal outcome in type 2 diabetic patients. Diabetologia 2006; 49: 1777-84.

  20. Chen Y, Su Y, Li C, Wu C, Lee M. A nationwide cohort study suggests chronic hepatitis B virus infection increases the risk of end-stage renal disease among patients in Taiwan. Kidney Int 2015; 87: 1030-8.

  21. Chen Y, Su Y, Li C, Hung S. 13-year nationwide cohort study of chronic kidney disease risk among treatment-naive patients with chronic hepatitis B in Taiwan. BMC Nephrol 2015; 16: 110.

  22. Kong X, Ma X, Su H, Xu D. Relationship between occult hepatitis B virus infection and chronic kidney disease in a Chinese population-based cohort. Chronic Dis Transl Med 2016; 2: 55-60.

  23. Ishizaka N, Ishizaka Y, Seki G, Nagai R, Yamakado M, Koike K. Association between hepatitis B/C viral infection, chronic kidney disease and insulin resistance in individuals undergoing general health screening. Hepatol Res 2008; 38: 775-83.

  24. Lee J, Lin M, Yang Y, Lu S, Chen H, Hwang S. Association of hepatitis C and B virus infection with CKD in an endemic area in Taiwan: a cross-sectional study. Am J Kidney Dis 2010; 56: 23-31.

  25. Cai J, Fan X, Mou L, Gao B, Liu X, Li J, Liu L, et al. Association of reduced renal function with hepatitis B virus infection and elevated alanine aminotransferase. Clin J Am Soc Nephrol 2012; 7: 1561-6.

  26. Lin M, Chiu Y, Lee C, Yu H, Chen H, Wu M, Hwang S. Factors associated with CKD in the elderly and non-elderly population. Clin J Am Soc Nephrol 2013; 8: 33-40.

  27. Senghore T, Su F, Lin Y, Chu F, Yeh C. Association between hepatitis B virus infection and chronic kidney disease in university students receiving physical check-ups: a cross-sectional study. J Exp Clin Med 2013; 5: 181-6.

  28. Zeng Q, Gong Y, Dong S, Xiang H, Wu Q. Association between exposure to hepatitis B virus and chronic kidney disease in China. J Int Med Res 2014; 42: 1178-84.

  29. Su S, Lin C, Kao S, Wu C, Lu K, Lai C, Yang H, et al. Risk factors and their interaction on chronic kidney disease: a multicentre case control study in Taiwan. BMC Nephrol 2015; 16: 83.

  30. Huang J, Chuang W, Dai C, Ho C, Hwang S, Chen S, Lin Z, et al. Viral hepatitis and proteinuria in an area endemic for hepatitis B and C infections: another chain of link? J Int Med 2006; 260: 255-62.

  31. Combes B, Shorey J, Barrera A, Stastny P, Eigenbrodt E, Hull A, Carter N. Glomerulonephritis with deposition of Australia antigen-antibody complexes in glomerular basement membrane. Lancet 1971; 2: 234-7.

  32. Amet S, Bronowicki J, Thabut D, Zoulim F, Bourliere M, Math urin P, de Ledinghen V, et al. Prevalence of renal abnormalities in chronic HBV infection:the HARPE study. Liver Int 2015; 148-55.

  33. Mallet V, Schwarzinger M, Vallet-Pichard A, Fontaine H, Corouge M, Sogni P, Pol S. Effect of nucleoside and nucleotide analogues on renal function in patients with chronic hepatitis B virus mono-infection. Clin Gastroenterol Hepatol 2015; 13: 1181-8.e1.

  34. Gane E, Deray G, Liaw Y, Lim S, Lai C, Rasenack J, Wang Y, et al. Telbivudine improves renal function in patients with chronic hepatitis B. Gastroenterology 2014; 146: 138-46.

  35. Tsai M, Chen C, Tseng P, Hung C, Chiu K, Chang K, Yen Y, et al. Does nucleos(t)ide analogues treatment affect renal function in chronic hepatitis B patients who have already decreased eGFR? A longitudinal study. PLoS One 2016; 11: e0149761.

  36. Mauss S, Berger F, Filmann N, Hueppe D, Henke J, Hegener P, Athmann C, et al. Effect of HBV polymerase inhibitors on renal function in patients with chronic hepatitis B. J Hepatol 2011; 55: 1235-40.

  37. Shin J, Kwon H, Jang H, Lee J, Gwak G, Huh W, Jung S, et al. Risk factors for renal functional decline in chronic hepatitis B patients receiving oral antiviral agents. Medicine 2016; 95: e2400.

  38. Wong G, Tse Y, Wong W, Yip T, Tsoi K, Chan H. Long-term safety of oral nucleos(t)ide analogues for patients with chronic hepatitis B: A cohort study of 53,500 subjects. Hepatology 2015; 62: 689-93.

  39. Turan I, Yapali S, Bademkiran F, Kose T, Duman S, Sozbilen M, Gunsar F, et al. Telbivudine in liver transplant recipients: renal protection does not overcome the risk of polyneuropathy and myopathy. Liver Int 2015; 21: 1066-75.

  40. Shimizu I, Kohno N, Tamaki K, Shono M, Huang H, He J, Yao D. Female hepatology: favourable role of estrogen in chronic liver disease with hepatitis B virus infection. World J Gastroenterol 2007; 13: 4295-305.

  41. Adinolfi L, Zampino R, Restivo L, Lonardo A, Guerrera B, Marrone A, Nascimbeni F, et al. Chronic hepatitis C virus infection and atherosclerosis: clinical impact and mechanisms. World J Gastroenterol 2014; 20: 3410-7.

  42. Wang C, Chen C, Lee M, Yang H, Hsiao C. Chronic hepatitis B infection and risk of atherosclerosis-related mortality: a 17-year follow-up study based on 22,472 residents in Taiwan. Atherosclerosis 2010; 2111: 624-9.

  43. Jacurska P, Drazilova S, Fedacko J, Pella D, Janicko M. Association between hepatitis B and metabolic syndrome: current state of art. World J Gastroenterol 2016; 22: 155-64.




2020     |     www.medigraphic.com